克拉功能化转移体用于改善皮肤透和Podophyllotoxin的沉积
Jiangxiu Niu1, Ming Yuan1, Liye Wang1
1College of Food and Drug, Luoyang Normal University, Luoyang, Henan 471934, PR China.
ACS omega
|September 15, 2025
概括
新的素功能化转移体 (POD-KTFs) 增强了生殖器的局部 podophyllotoxin (POD) 输送. 这些新型配方增加皮肤沉积,同时最大限度地减少全身吸收,提供更安全,更有效的治疗选择.
科学领域:
- 皮肤病学 皮肤病学
- 药品制造 药品制造 药品制造
- 纳米技术纳米技术
背景情况:
- 波多菲洛毒素 (POD) 是生殖器的关键治疗方法.
- 由于皮肤吸收,传统的POD染料会引起全身不良反应.
- 需要改进局部输送系统,以提高疗效和减少副作用.
研究的目的:
- 开发和描述POD载基氨酸功能化转移体 (POD-KTF).
- 评估POD-KTFs的皮肤透,沉积和分布.
- 评估POD-KTF对皮肤结构的影响,并将其与传统配方进行比较.
主要方法:
- POD-KTF (水力动力直径,表面潜力,SEM,XRD) 的配方和表征.
- 使用猪耳皮进行体外皮肤透和沉积研究.
- 用库马林-6进行皮内光成像,以可视化药物分布.
- 评估角层 (SC) 的结构变化.
主要成果:
- POD-KTFs表现出球形形态,其水力动力直径为183.1 nm,表面电位为-33.9 mV.
- POD-KTFs显著增加了猪皮中的POD沉积量 (2.14x与染料相比,1.80x与POD-TFs相比).
- 与POD和POD-TF相比,POD-KTFs显著减少了POD的通过皮肤透.
- 光成像显示POD-KTFs主要局限于表皮, SC破坏最小.
结论:
- 克拉功能化转移体为局部POD输送提供了一种有效的策略.
- POD-KTFs增强了表皮药物沉积,并减少了全身吸收.
- 这种方法有望改善局部POD治疗的治疗结果.
更多相关视频
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
188
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
188
01:19Clinical Applications of Epidermal Stem Cells
3.3K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.3K
01:06Carrier-Mediated Transport
1.2K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.2K